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We have recently shown (1) that the specificities of cloned human CTL can be 
altered by incubating them with heteroaggregates containing anti-T3 covalently 
crosslinked  to  nominal  anti-target  cell antibodies.  Such heteroaggregates  link 
the target cells directly to T3  molecules on the effector cells,  leading to both 
conjugate formation and target cell lysis.  T3 is a subunit of the T  cell receptor 
complex (2, 3), and previous experiments (4) demonstrated that a direct linkage 
of the target to T3 would trigger  lysis.  By using appropriate  heteroaggregates, 
cloned CTL could be made to lyse almost any specified target, including alloge- 
neic and xenogeneic tumor cells and chicken red blood cells (CRBC)  1 (1). Since 
it is unlikely that each of the CTL clones used in those experiments recognized 
MHC antigens on all of the target cells, it was concluded that MHC components 
were  not  involved  in  heteroaggregate-dependent  lysis.  On  the  other  hand,  a 
direct linkage of the target cell to the T  cell receptor complex was a requirement 
for lysis; crosslinking  target  cells to other effector cell surface components did 
not lead to target cell iysis, even under conditions where effector/target conju- 
gates could be demonstrated.  Similar  results  have recently been published  by 
Staerz et ai. (5), who showed that, in murine cells, heteroaggregates that crosslink 
the antigen-specific portion of the T  cell receptor complex (Ti) with target cells 
also promote target cell lysis. 
In this paper,  we study lysis mediated by normal  human  peripheral  blood T 
cells that  have been sensitized  with anti-Tg-containing  heteroaggregates.  It is 
known that  human peripheral  blood T  cells will  mediate lectin-dependent  lysis 
(6); we asked whether sensitized T  cells are also competent cytolytic effectors, or 
are  instead  precursors  that  must  first  differentiate  and/or  proliferate  before 
mediating  lysis.  Here,  we show that  sensitized  peripheral  blood T  cells are,  in 
fact, potent cytolytic effectors when taken directly from the blood, but that brief 
(2-4  h)  exposure  to  IL-2  can  markedly  enhance  their  cytolytic activity.  Our 
results suggest a strategy for attacking tumor cells and other pathogenic cells in 
vivo with sensitized autologous lymphocytes. 
P. Perez is the recipient of a Fulbright Fellowship  awarded by the Spanish Department of Education 
and Culture. Address reprints requests to D. M. Segal, Bldg. 10, Rm. 4B17, National Institutes of 
Health, Bethesda, MD 20892. 
1  Abbreviations used in  this paper:  CRBC, chicken red blood cells; LAK, lymphokine-activated 
killer; SPDP, N-succinimidyl-3-(2-pyridyldithiol)  propionate. 
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Materials and  Methods 
Crosslinked Antibodies.  Anti-T3 (OKT3), anti-K  k (36-7-5), and anti-DNP were purified 
as described (1). Anti-class I (W6132), an anti-HLA class I framework antibody (7), was 
purified using a procedure like that for anti-T3. The Fab fragments of anti-T3 and anti- 
DNP were prepared by incubating the proteins for 4 h at 37 °C with a 1:100 (wt]wt) ratio 
of papain/Ig in 0.1  M sodium phosphate, 0.1  M NaCI, 1 mM EDTA, 20 mM cystein, pH 
8.0. The reaction was terminated by adding iodoacetamide to a final concentration of 30 
raM. Analysis by SDS-PAGE indicated that the proteins had been completely digested to 
50 kD fragments. They were then dialyzed against 0.1  M  Tris]CI, pH 8.5, and passed 
over a protein A-Sepharose column to remove Fc fragments and trace contaminants of 
intact IgG. Proteins were crosslinked as described (8) using the heterobifunctional cross- 
linking reagent, SPDP. A threefold molar excess of SPDP to protein, for both intact Ig 
and their Fab fragments, was used in all cases. After the crosslinking step, a small amount 
of iodoacetamide was added, and each sample was applied to a 1.6 × 90 cm Ultrogel AcA 
22 (LKB Instruments, Inc., Gaithersburg, MD) column to remove the monomeric IgG. 
In most experiments, a fraction containing mostly dimers and trimers was used. However, 
larger aggregates were equally active and were used in some experiments. We refer, in 
this paper, to crosslinked antibody preparations as antibody I  x  antibody 2. The prepa- 
rations used were anti-T3 X anti-K  k, anti-T3 X anti-DNP, anti-T3 (Fab) × anti-DNP (Fab), 
and anti-class I x  anti-DNP. 
Target Cells.  Four target cells were used in this paper; RDM4 and EL4 are, respec- 
tively, H-2  k and H-2  b murine T cell lymphomas, and M 16 (9) is a human EBV-transformed 
lymphoblastoid cell line.  CRBC were also used as targets.  In some experiments, target 
cells were modified with TNP by incubating them with 3 mM trinitrobenzene sulfonate 
for 10 min at 37°C in PBS, pH 7.4. Cells were 5~Cr-labeled as described (10). 
Effector Cells.  Mononuclear cells were isolated from freshly drawn, heparinized veinous 
blood from normal donors  by density  gradient  separation over Ficoll-Hypaque (LSM; 
Litton Bionetics, Kensington, MD). Monocytes were depleted by passage over Sephadex 
G10 as described (11), yielding a lymophocyte preparation. The Leu-11 ÷ cells (including 
most of the NK activity) were removed from the lymphocytes by incubating them with 
anti-Leu-11 b (Becton, Dickinson & Co., Mountain View, CA) and rabbit complement (Pel 
Freeze, Rogers, AK) using Becton Dickinson's suggested protocol. 
In some experiments, large numbers of cells were obtained from a normal donor by 
leukapheresis. In those experiments, cells were cryopreserved and stored in liquid nitrogen 
(12) as either mononuclear cells, lymphocytes, or Leu-11-depleted lymphocytes. 
Depletion ofT4  ÷ and T8  + Cells.  Frozen Leu-11-depleted lymphocytes were thawed and 
washed.  Cells (2  x  106 cells/ml) were then incubated for 30  min at room temperature 
with a  1:100 dilution (final concentration) of ascites produced by either OKT4 or OKT8 
hybridomas (ascites were a kind gift from Dr. William Biddison). Rabbit complement was 
added to a  1:10 final concentration. Cells treated with OKT8 were incubated for 60 rain 
at 37°C and washed. Cells treated with OKT4 were incubated 30 rain at 37°C, washed, 
and treated an additional 45 rain with fresh complement. 
Analyses of Cell Populations.  Cell preparations were analyzed by flow cytometry for the 
expression of the  M1,  T3, T4, T8, and  Leu-11  antigens by using FITC derivatives of 
mAb  OKM1,  OKT3,  OKT4  (Ortho  Diagnostics,  Raritan,  NJ),  Leu-2,  and  Leu-lla 
(Becton, Dickinson & Co.), respectively. Ceils (I-3 X 10  ~) were pelleted and resuspended 
in 25 #1 of FACS medium (HBSS without phenol red containing 2.5%  BSA and 0.2% 
sodium azide) containing a saturating concentration of the appropriate FITC-antibody. 
After 30-rain incubation at 0°C,  cells were washed twice, resuspended in  1 ml of cold 
FACS medium, and analyzed with a FACS II cell sorter (Becton Dickinson Immunocyto- 
metry Systems, Mountain  View, CA) as described (13).  Control cells were prepared by 
incubating  the  cells with  an  irrelevant  FITC-antibody of the  same isotype as the  test 
antibody. 
Incubation  of Effector Cells with Lymphokines.  In an early experiment, cells were incu- 
bated with delectinated human T  cell growth factor (Cellular Products, Buffalo, NY). In 
most experiments, however, recombinant human IL-2 (Cetus, Emeryville, VA; a gift from 168  CYTOTOXIC T  CELL TARGETING BY  CROSSLINKED ANTIBODIES 
Dr.  Steven  Rosenberg) was  used.  We also tested recombinant human  IFN-~,  (Biogen, 
Cambridge, MA;  a  gift from Dr.  Michael Lotze) for activity. In the short-term kinetic 
assay,  10-ml aliquots of Leu-1 i-depleted lymphocytes (106 cells/ml) were incubated in 25- 
cm  2 tissue culture flasks in RPMI  1640 containing 10%  FCS,  10 mM Hepes, 50 ~M 2- 
ME, glutamine, pyruvate, nonessential amino acids, penicillin, and streptomycin (culture 
medium). All flasks were incubated for 24 h  in a  37°C CO2 incubator, and at various 
intervals, recombinant IL-2 (final concentration, I0 U/ml) was added to a different flask. 
After 24 h, all flasks were harvested and the cells were tested for cytotoxic activity. Long- 
term assays for activation were done similarly, except that all cells were incubated for a 
total of 3 d, and IL-2 was added at 1-d intervals. 
Cytotoxicity Assays.  Cytotoxicity was  measured in culture medium  using 96-well,  U- 
bottom microtiter plates (10).  To each well was added varying numbers of effector cells 
in  100 #i medium, followed by 20 #i of antibody or medium and either 104 or 5 x  103 
5tCr-labeled target cells in  100 t~l medium. Plates were incubated for 4 h at 37°C in 5% 
CO2,  100%  humidity. Supernatants were harvested with a  Titertek harvesting system 
(Skatron, Sterling, VA) and counted in a well-type gamma counter. Triplicate determi- 
nations were made for each sample. Maximum lysis was measured by incubating target 
cells  in  5% Triton X-100, and spontaneous release was determined by incubating the 
target cells in medium alone. Percent lysis was calculated as 100 x  [(experimental release 
-  spontaneous release)/(maximum release -  spontaneous release)]. In some experiments, 
curves of percent lysis vs. E/T were analyzed by fitting them to a  hyperbolic function 
using the MLAB program (14). 
Results 
Lysis of Target Cells by Heteroaggregate-treated Peripheral Blood  T  Cells.  We 
have previously shown (1) that cloned human CTL, when coated with anti-T3 X 
anti-target cell antibody would specifically lyse cells expressing epitopes recog- 
nized by the antitarget antibody. To determine whether human peripheral blood 
T  cells could also be rendered cytotoxic for specified targets with appropriate 
crosslinked  antibodies,  mononuclear  cells  were  incubated  with  ~Cr-labeled 
RDM4 in the presence of anti-T3 X anti-K  k or with ~lCr-labeled TNP-RDM4 in 
the presence of anti-T3  X anti-DNP (Table I). In both cases, the mononuclear 
cells lysed the  target cells when  crosslinked antibody was present,  but did not 
mediate  lysis  in  the  absence  of  antibody.  However,  mononuclear  cells  also 
mediated ADCG, as shown by target cell lysis in the presence of anti-K  k (which 
is an IgG2a antibody). Since the crosslinked antibodies possessed Fc fragments, 
it was possible that tumor cell lysis in the presence of the antibody heteroaggre- 
gate  represented  ADCC  (15)  and  not  lysis  mediated  by  sensitized  peripheral 
blood T  cells.  To eliminate this possibility, mononuclear ceils were first passed 
over Sephadex G10 to remove monocytes. This removed essentially all of the 
cells falling within the OKM1  bright peak (i.e., monocytes [13] (Table II). As a 
result  of monocyte depletion,  ADCC  activity was  substantially  reduced,  while 
heteroaggregate-dependent  lysis  increased  (Table  I).  An  aliquot  of the  G10- 
passed cells was then treated with anti-Leu-1 l b  and complement to remove the 
K, NK subset of cells. (The Leu-11  epitope is on the neutrophil and K cell Fc3, 
receptor,  but  not  on  monocyte Fc'),  receptors [16].)  This  treatment  removed 
>70%  of the  Leu-11 + cells and all of the remaining ADCC  activity, (Table I), 
leaving a  population  of lymphocytes that  was  87%  T3  + (Table II),  and  which 
required the anti-T3-containing heteroaggregate to mediate lysis. 
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TABLE  I 
Heteroaggregate-dependent  Lysis of RDM4 Cells by Peripheral Blood T Cells 
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Exp. 
Percent lysis with various effectors 
Monocyte-de-  Leu-1 l-de- 
Antibody  Mononuclear  pleted cells  IL-2-acti- 
cells  (lympho-  pleted lyre-  vated cells  0 
cytes)*  ph°cytes* 
1 u 
2  ~ 
None  -0.6  1.8  -0.3  4.6 
Anti-T3 x anti-K  k  10.1  16.2  26.0  43.2 
Anti-K  k  18.5  8.4  -2.3  3.9 
None  -1.8  -1.0  -1.4  3.1 
Anti-T3 X anti-DNP  6.2  7.5  8.4  38.2 
Anti-K  k  5.7  2.1  0.0  2.6 
* Depleted by passage over Sephadex G 10. 
~: Depleted by treatment of the G 10-passed cells with anti-Leu-11  b and complement. 
! Leu-11-depleted lympbocytes were incubated overnight with 50 (Exp.  1) or 30 (Exp. 2) U/ml of 
recombinant IL-2. 
t Tested against ~Cr-labeled RDM4 at an E]T ratio of 20:1  in a 4-h assay. Anti-T3 × anti-K  k and 
anti-K  k were added to wells at 10 and 5 #g/ml final concentrations, respectively. Anti-K  k is 36-7-5, 
a mouse IgG2a mAb. 
Same as in Exp. 1 except targets were TNP-RDM4, and anti-T3 x anti-DNP was used at 5 #g/ml. 
Effector cells were from a different donor than in Exp. 1. 
TABLE  II 
Compositions of Human Peripheral Blood Effector Populations 
Marker 
Percent positive cells using various effec- 
tors 
Mononuclear  Monocyte-de-  Leu-11-de- 
cells  pleted cells  pleted lym- 
(lymphocytes)  phocytes 
M 1 (bright)  16.4  0.4  0.5 
T3  66.1  84.1  87.1 
T8  27.1  32.6  34.0 
Leu-11  (bright)  5.1  5.6  1.6 
Cells used in Exp.  1, Table I were stained for M1, T3, T8, and Leu-11 
expression with FITC-labeled OKM1, OKT3, Leu-2, and Leu-1 la anti- 
bodies, respectively, and analyzed by flow cytometry. Mononuclear cells, 
in addition to the bright peak, gave a Leu-11  dull peak that was removed 
by passage over Sephadex G 10 and was presumably due to Fc binding. 
lytic activity of T  cells increased after overnight incubation with crude lympho- 
kine-containing  supernatants.  The  data  in  Table  I  and  Fig.  1  show  that  lysis 
mediated  by sensitized T  cells was also markedly  enhanced  by overnight  incu- 
bation  with  recombinant  IL-2.  IL-2  also  elicited a  small  amount  of antibody- 
independent  lysis (Table I). This presumably arose from the contaminating Leu- 
1 1 + cells remaining  after treatment  with anti-Leu-1 l b  and  complement  (Table 
II). Fig.  1 shows that,  unlike IL-2, recombinant  human  IFN-3, did not stimulate 
lysis mediated  by heteroaggregate-treated  T  cells. However,  in this same exper- 
iment  (data not  shown),  IFN-3, elicited a  twofold  increase in  ADCC  activity in 170  CYTOTOXIC  T  CELL  TARGETING  BY  CROSSLINKED  ANTIBODIES 
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FIGURE  1.  Stimulation by IL-2 oflysis mediated by heteroaggregate-treated peripheral blood 
T  cells. Human PBL were depleted of Leu-11 + cells and tested for lysis against RDM4 cells in 
the presence of anti-T3 x anti-K  t (10 #g/ml). Cells were incubated overnight at 37 °C with (A) 
medium, (F-l) 50 U/ml recombinant IL-2, or (O) 100 U/ml recombinant IFN-7. In control 
experiments (not shown) lysis  was not observed in tbe absence of  antibodies, while  ADCC (lysis 
in the presence of anti-K  k) was detectible only after incubation with IL-2, and at E/T ratios of 
40:1 (9.4%) and 20:1 (3.9%). 
TABLE  III 
Specificity of Lysis by Heteroaggregate-treated Peripheral Blood T Cells 
Antibody 
Percent lysis of various targets 
RDM4  TNP-RDM4  M 16  TNP-M 16  EL-4 
None  -2.3  4.5  2.7  3.0  3.3 
Anti-T3 X anti-K  k  36.3  60.3  3.5  --  -- 
Anti-T3 X anti-DNP  -0.9  59.6  4.1  58.1  2.3 
Leu-I 1- lymphocytes were incubated 18 h  with 100 U/ml of recombinant IL-2. Lysis was assayed in 
a  4-h ~lCr-release assay at an E/T ratio of 20:1. --, not done. 
the unfractionated mononuclear cells and in the lymphocytes before treatment 
with anti-Leu-1 1  b and complement. 
Specificity of Lysis.  IL-2-activated, Leu-11- lymphocytes were rendered specif- 
ically cytotoxic for designated targets by crosslinked antibodies (Table III). Thus, 
effector cells incubated with anti-T3  X anti-K  k lyse only targets expressing the 
H-2K  k molecule (RDM4 and TNP-RDM4),  while cells incubated with anti-T3 X 
anti-DNP  lyse  only TNP-modified  target  cells.  As  was  previously  shown  for 
cloned CTL (1), heteroaggregate-coated peripheral blood T  cells are able to lyse 
both human and murine tumor cells. 
In a  second experiment, heteroaggregate-treated T-cells were tested for the 
ability to lyse innocent bystander cells.  Effector cells sensitized with anti-T3  x 
anti-DNP  lysed TNP-RDM4,  but  not  unmodified RDM4,  as  expected  (Table 
IV).  The  important  point  was  that  the  innocent  bystander cells  (5~Cr-labeled 
RDM4) were not lysed in the presence of unlabeled TNP-RDM4. 
Finally, we asked whether heteroaggregates containing anti-effector cell anti- 
bodies other than anti-T3 would stimulate lysis. Heteroaggregates containing an 
anti-human HLA class I framework antibody neither mediated lysis nor blocked 
lysis mediated by anti-T3 x anti-DNP (Table V). This, along with previous results 
(1) showing that cloned human CTL do not lyse targets attached to either T4 or PEREZ  ET  AL.  171 
TABLE IV 
Heteroaggregate-coated Human T Cells Do Not Lyse Innocent 
Bystander Cells 
E/T ratio 
Unlabeled TNP-  Percent lysis of labeled targets* 
RDM4 added*  TNP-RDM4  RDM4 
10  -  22.0  2.2 
5  -  13.2  0.3 
2.5  -  8.9  -2.8 
10  +  ND  0.2 
5  +  ND  -0.6 
2.5  +  ND  0.5 
Effectors are Leu-11- lymphocytes after overnight incubation with  100 
U/ml recombinant IL-2. They were incubated for  1 h  at 24°C with  15 
~g/ml of anti-T3 x  anti-DNP, and washed before being added to target 
cells. E/T ratios are based upon the total number of target cells, labeled 
plus unlabeled. 
* Samples designated positive contain 104 unlabeled TN P-RDM4 cells per 
well. 
* All wells contained  104 51Cr-labeled target cells. ND, not done. 
TABLE  V 
Lytic Requirement  for Anti-T3 in Heteroaggregates 
Antibody* 
Percent lysis of various targets* 
TNP-  TNP-  CRBC  RDM4  CRBC  RDM4 
None  -1.3  1.9  -1.0  6.6 
Anti-T3 ×  anti-DNP  -1.3  20.6  0.6  16.3 
Anti-class I X anti-DNP  0.1  2.7  -1.2  7.7 
Anti-T3 ×  anti-DNP +  anti-class I x  anti-DNP  --  27.4  --  14.8 
Anti-T3 ×  anti-DNP +  anti-class I  --  18.9  --  19.1 
* Heteroaggregates were added to a final concentration of 5 t~g/ml. When two antibody preparations 
were present, each was at 5 ~g/ml. 
* Leu-11- lymphocytes were  used as effectors in a  4-h ~lCr-release assay at an E/T  ratio of 2.5:1. 
--,  not done. 
TNP  groups  on effector cells,  strongly  suggest that  the  target  cell must bind 
directly to the  T  cell receptor complex for iysis to occur.  Table  V  also shows 
that human peripheral blood T  cells lyse TNP-CRBC when coated with anti-T3 
X  anti-DNP.  This  suggests  that  MHC  components  are  not  involved  in  lysis 
mediated by heteroaggregate-coated effector cells, since it is unlikely that CRBC 
express MHC antigens  that  could be recognized by an appreciable fraction  of 
human CTL. 
Heteroaggregate-dependent  Peripheral Blood Effector T Cells Are T8  +.  Sensitized 
effector T  cells were further characterized for the expression of T4 and T8 (Fig. 
2),  Leu-11-depleted  lymphocytes were  treated  with  either  anti-T4  or anti-T8 
and complement, and were tested for the ability to lyse TNP-RDM4 cells in the 
presence of anti-T3 (Fab) X anti-DNP (Fab). Fig. 2 shows that untreated lympho- 
cytes are  moderately lytic, but that  IL-2 greatly increases their  lytic potential. 
Removal of the T4  + population enhances activity, both in the presence or absence 172  CYTOTOXIC  T  CELL  TARGETING  BY  CROSSLINKED  ANTIBODIES 
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FIGURE  2.  Sensitized  peripheral  blood  effector  T  cells  are  T8 ÷.  The  lytic  activity  of an 
aliquot of Leu-I I- lymphocytes  (PBL)  was tested after overnight  incubation in the presence 
(0) or absence  (a,) of I00  U/ml  recombinant  IL-2. Another aliquot was treated with anti-T4 
and complement  and tested for  lysis with (A) or without (II) IL-2  treatment.  A  final sample 
was  treated  with  anti-T8  and  complement,  and  tested  with  (O)  or  without  (I-I)  an  IL-2 
incubation. Targets  were 5JCr-labeled TNP-RDM4.  Lysis was measured in a  4-h 5~Cr-release 
assay in the presence of 5 #g/m] of anti-T3 (Fab) x  anti-DNP (Fab). 
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FIGURE 3.  Kineticsofactivationofheteroaggregate-treatedperipheralbloodeffectorTcells 
by IL-2.  Leu-I 1-depleted lymphocytes were incubated in four different flasks for a total of 3 
d  in  culture.  At  1-d  intervals,  different  flasks  received  100  U/ml  (final  concentration)  of 
recombinant IL-2. Flask  1 received IL-2 at the beginning of the culture period, while flask 4 
received  no IL-2.  At the end  of the  3-d culture period,  cells were harvested and tested for 
lysis against RDM4 cells in the presence (A) or absence ((3) of 10 #g/ml anti-T3  ×  anti-K  k, at 
an E/T of 2.5:1. 
of IL-2, while treatment with anti-T8 and complement totally abrogates all lytic 
activity.  This experiment  demonstrates  that,  within the sensitivity of the assay, 
all of the heteroaggregate-dependent  lysis is mediated by T  cells that express the 
T8  antigen.  By using the  Fab-containing  heteroaggregate,  we have  eliminated 
the possibility that ADCC has contributed to the lytic process in this experiment. 
Kinetics of  Activation of Sensitized T Cells by IL-2.  The kinetics of activation of 
heteroaggregate-coated  T  cells  by IL-2 are  shown in Fig.  3.  The activation  of 
lytic  activity  increased  rapidly  with  time,  being  nearly  complete  after  1  d  of 
incubation with IL-2. We found large variations between donors in the extents 
of activation  of sensitized  CTL  in  the  absence  of IL-2.  For  example,  in  the 
experiments shown in Fig. 3 and in Exp.  ! of Table I, the ability of unstimulated PEREZ  ET  AL.  173 
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FIGURE 4.  Short-term activation  of sensitized peripheral blood T  cells by  IL-2.  Leu-I l- 
depleted lymphocytes were incubated for various periods with IL-2 as in Fig. 3, except that 
the total period of incubation was 24 h. Lysis was measured against SlCr-labeled TNP-RDM4 
in the presence of 10 #g/ml anti-T3 × anti K  * (A) or 5 #g/ml anti-T3 (Fab) × anti-DNP (Fab) 
(B). Times of incubation with IL-2 are indicated. In the experiment shown, FCS was used as 
the serum supplement to the culture medium; similar results were obtained when human AB  + 
serum was used. 
cells to mediate lysis in the presence of crosslinked antibody was relatively high, 
and increased by less than twofold upon incubation with IL-2. In contrast, cells 
from  the donors  shown in  Table  I,  Exp.  2,  Fig.  1,  and  Fig.  2  were relatively 
inactive before stimulation,  and showed much greater increases in lytic activity 
after incubation with IL-2. Antibody-independent lysis of the RDM4 tumor cells 
began to appear at day 2 and increased further by day 3 (Fig. 3). This presumably 
represents  lymphokine-activated  killer (LAK) activity (I 7,  18), and constituted 
less than one-eighth the total activity (in lytic units) on day 3. 
Since most of the activation of sensitized T  cells by IL-2 occurred within the 
first day of stimulation,  we followed lysis at shorter intervals.  Leu-11- lympho- 
cytes were tested for the ability to lyse RDM4 cells in the presence of anti-T3  x 
anti-K k or TNP-RDM4 cells in the presence of anti-T3  (Fab) x  anti-DNP (Fab). 
Experiments were done in medium containing either  10% FCS or  10% human 
AB  ÷ serum. Fig. 4 shows that substantial activation occurs after 1-4 h incubation 
with  IL-2,  and  increases  slowly thereafter.  Similar  results  were obtained  with 
human serum as the serum component in the culture medium (data not shown). 
The  percent  lysis  vs.  E/T  curves  can  be  fit  within  experimental  error  to  a 
hyperbolic function; IL-2 causes an increase in the maximum lysis and a decrease 
in the E/T ratio required for half-maximal  lysis. 
Retention  of Lyric Activity  by Heteroaggregate-coated  T  Cells.  Because  of the 
potential for in vivo use of sensitized effector cells, it is important  to know how 
long after treatment  with the heteroaggregate  T  cells can retain  activity when 
incubated at 37°C. To test this,  Leu-11- lymphocytes were activated with IL-2 
and divided into two portions,  one of which was incubated with anti-T3  ×  anti- 
K K, the other with medium alone. The cells were then washed and incubated for 
0, 4,  8, or 24 h  at  37°C and tested for lytic activity against RDM4. As seen in 
Table VI, the sensitized cells retained  considerable activity even after 24 h.  In 
this experiment, different target cell preparations were used to assay lytic activity 
at the various times of incubation.  To correct for variations in lysability of the 
target cell preparations, as well as for variations in effector cell activity unrelated 
to bound heteroaggregate,  untreated control effector cells were tested for lytic 
activity in the presence of freshly-added heteroaggregate.  Table VI shows that 174  CYTOTOXIC  T  CELL  TARGETING  BY  CROSSLINKED  ANTIBODIES 
TABLE  VI 
etain Activity During Incubation at 37 °C 
Treatment with 
heteroaggregate*  Percent lysis at various times of incubation (h) at 37 ° C* 
Precoat  §  In medium !  0  4  8  24 
-  -  2.2  3.7  4.5  6.5 
-  +  33.7 (5.3)  51.4 (7.4)  42.4 (4.4)  21.9 (1.3) 
+  -  33.0 (4.3)  46.6 (4.3)  48.5 (5.0)  31.4 (2.4) 
+  +  32.0 (5.6)  44.3 (3.9)  49.2 (3.9)  21.4 (1.4) 
* Anti-T3 ×  anti-K  k 
* Percent lysis of RDM4 cells by  IL-2-activated, Leu-11- lymphocytes at E/T  ratio of 20:1.  Lytic 
units, defined as the initial slope of a  hyperbolic fit to the E/T dose-response curve, are indicated 
in parentheses, where measurable. Effector cells were activated by overnight incubation with 100 
U/ml recombinant IL-2. 
0 Effector cells were incubated  1 h  at 0°C with (+) or without (-) 20 #g/ml heteroaggregate and 
washed before incubation at 37°C. 
! Heteroaggregate (5 #g/ml) was either present (+) or absent (-) in the lytic assay medium. 
variations in lytic activity of the sensitized test cells paralleled those of the control. 
This  suggests that  variations  such as the  loss in activity after  24  h  incubation 
were not  due  to a  loss of bound heteroaggregate,  but  were instead  due to a 
heteroaggregate-independent  process  such  as  the  downregulation  of activity 
following the removal of cells from IL-2. 
Discussion 
Our results show that freshly purified circulating  human peripheral  blood T 
cells actively lyse tumor targets when incubated with anti-T3-containing antibody 
heteroaggregates, and that the specificity of lysis is dictated by the specificity of 
the antibody to which the anti-T3  is linked.  Sensitized effectors from different 
donors vary in  their  lytic activities,  but high  levels of activity can be obtained 
from all cell samples by incubating them for a few hours with crude lymphokine- 
containing  supernatants  or with  recombinant  IL-2,  but not with  recombinant 
IFN-% The effector cells that mediate heteroaggregate-dependent  lysis express 
the  T8  antigen,  since  treatment  with  anti-T8  plus  complement  removes  all 
measurable lytic activity. However, our data do not preclude the possibility that 
a small subset of the cells mediating heteroaggregate-dependent  lysis is T4 +. In 
this  respect,  heteroaggregate-coated  T  cells resemble normal  CTL,  where the 
great majority are T8 + (2,  19,  20).  On  the other hand,  it is known  that  some 
T4 + cells can mediate lysis (1, 21-24) and that a few cells are both T4 + and T8 + 
(25). 
The T8 + cells represent approximately one-third of the Leu-11- lymphocytes 
used in thse studies. Therefore, at most, one-third of the sensitized T  cells could 
potentially mediate  target  cell  lysis.  It is not known  whether all  T8 ÷ cells are 
cytolytic, but the activity of sensitized peripheral  blood T  cells approaches that 
of many of the cloned CTL that  we have tested, suggesting that  the lytic cells 
are not a minor subset of the T8 + cells. Even before IL-2 stimulation, heteroag- 
gregate-coated T  cells from most donors exhibit appreciable lytic activity, dem- 
onstrating that circulating  human  T  cells contain a substantial  fraction of corn- PEREZ  ET  AL.  175 
petent  lytic  cells  that  do  not  require  proliferation  or  differentiation  to  be 
activated. IL-2 can further activate these cells, but this occurs so rapidly that it 
probably involves neither cellular proliferation nor differentiation. Similar con- 
clusions were drawn from earlier studies (6) of lectin-dependent killing of tumor 
targets and chicken red blood cells by human PBL. In those studies, lytic activity 
was also detected in freshly prepared cell samples. 
Interestingly, resting splenic T  cells in the mouse apparently exist in a different 
activation state than peripheral blood T  cells in the human. In the mouse, spleen 
cells are  unable  to  mediate either  iectin-dependent (26)  or  heteroaggregate- 
dependent (5) lysis unless they have been preincubated for several days with IL- 
2 and iectin. Erard et al. (27) have recently presented strong evidence that shows 
that  resting  murine  T  cells  must  both  proliferate  and  differentiate  before 
becoming competent mediators of lectin-dependent lysis, in striking contrast to 
circulating human peripheral T  cells (6). 
From the results of this  paper,  we can  begin  to  design a  protocol  for the 
treatment  of cellular  pathogens  or  tumor  cells  with  sensitized  T  cells.  For 
example, we envision that a reasonably specific antitumor mAb could be cross- 
linked with anti-T3. PBL could be obtained from a cancer patient by leukapher- 
esis,  treated briefly with IL-2, and coated with the anti-T3 X antitumor heter- 
oaggregate (in a  future communication [P.  Perez, J.  A. Titus,  M. T.  Lotze, F. 
Cuttitta,  D.  L.  Longo, E. S.  Groves, H.  Rubin,  P. J.  Durda, and D.  M.  Segal, 
manuscript submitted for publication] we will show that such cells will lyse human 
tumor cells in vitro).  These cells could then be reintroduced into the patient, 
either  locally or  systemically, where,  if they home to  the  tumor  mass  or  to 
secondary metastases, they would lyse the tumor cells. Such a procedure poten- 
tially would be a very efficient use of antibody. For example, 108 T  cells, each 
with 105 T3 molecules on its surface, would bind, at saturation, a maximum of 
5 ~g of crosslinked antibody. Moreover, as shown in Table VI, bound heteroag- 
gregate would be expected to remain an effective targeting agent in vivo for at 
least  24  h  (with the caveat that cells of the reticuloendothelial system might 
modulate the heteroaggregate from the T  cell surface [28]). The heteroaggre- 
gate-coated effector T  cells, because of their high abundance, should be a much 
stronger source of lytic activity than either NK cells or  LAK cells, which, in 
vitro, require much higher E/T ratios to mediate lysis than do sensitized effector 
T  cells (18, 29, 30). 
Heteroaggregate-coated cytotoxic cells were originally used (8,  10, 31, 32) to 
cause ADCC effector cells to lyse specified targets.  In those studies, we found 
that  heteroaggregates containing anti-Fc3,  receptor antibodies  crosslinked to 
anti-target cell antibodies rendered ADCC effectors specifically lytic for target 
cells that bound the antitarget antibody, and only heteroaggregates containing 
anti-Fc3, receptor antibodies would promote lysis (8). Since two markedly differ- 
ent cytotoxic cells (ADCC effectors and CTL) behave similarly when coated with 
heteroaggregates against  the  appropriate  receptor  (Fc3, receptor  for  ADCC 
effectors or T  cell receptor complex for CTL), we suspect that most cytotoxic 
cells could be specifically targeted to any designated pathogen using this strategy. 
Moreover, anti-T3-containing heteroaggregates should, in principle, be able to 
target helper T  cells to a lesion where they could maintain, through the produc- 176  CYTOTOXIC  T  CELL TARGETING  BY  CROSSLINKED ANTIBODIES 
tion of lymphokines, high levels of activity within the cytotoxic cell populations. 
Thus, by using the proper heteroaggregates and cell mixtures, it may be possible 
to engineer a strong and specific response against pathogenic entities which, for 
a variety of reasons, might normally be resistant to immunological destruction. 
Summary 
Antibody heteroaggregates have been used to render human peripheral blood 
T  cells lytic for specified targets.  The heteroaggregates contain anti-T3  cova- 
lently linked to antibodies against nominal target cell antigens. Such heteroag- 
gregates bind target cells directly to T3  molecules on effector cells and trigger 
target  cell  lysis.  Freshly  prepared  human  PBL,  when  coated  with  anti-T3- 
containing heteroaggregates, are lytic without further stimulation, although brief 
exposure to crude lymphokine-containing supernatants or recombinant IL-2, but 
not recombinant IFN-% enhances the activity. The effector ceils are T8 +, and 
when fully stimulated, their lytic activity approaches that of some cloned CTL. 
When T  cells are treated with heteroaggregate, washed, and incubated at 37 °C 
in medium not containing heteroaggregate, they retain activity for at least 24 h. 
The results of this study suggest a  strategy in which heteroaggregate-coated T 
cells could be used in vivo to mount a lytic response against pathogenic cells such 
as tumor ceils or virus-infected cells. 
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